Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

238 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-06

Study Completion Date

2021-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Analysis of freely circulating DNA in liquid biopsies using the BEAMing method

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

NCT02758951

Colorectal Neoplasm Colorectal Cancer Colorectal Neoplasms Malignant +8 more

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer

NCT01493713

Colorectal Cancer Hepatic Metastasis

COMPLETED PHASE4

Pelvic Drain After Rectal Resection for Mid-low Rectal Cancer

NCT04573621

Rectal Cancer

UNKNOWN NA

Metachonous Peritoneal Carcinomatosis Incidence After Curative Surgery for pT4 Colon Cancer Patients

NCT05300789

Peritoneal Carcinomatosis Colon Cancer

COMPLETED

Metabolomic Phenotyping After Surgery for Colon Cancer: Study of Novel Predictive Biomarkers

NCT02789709

Colon Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Analysis of freely circulating DNA in liquid biopsies using the BEAMing method is proposed as a technique that may be useful for analysing the RAS mutation status in different types of cancer. However, first it is necessary to evaluate the concordance between the results obtained in tumour samples and liquid biopsies.

Primary objective

• To evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild-type metastatic colorectal cancer.

Secondary objectives

* To evaluate the appearance of new RAS mutations using liquid biopsies at the moment of disease progression.
* To evaluate the appearance of new RAS mutations using liquid biopsies prior to radiological documentation of disease progression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

RAS Wild Type mCRC

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RAS wild-type subjects

The blood samples will be collected according to the site's routine clinical practice usually prior to each treatment cycle and at the follow-up visits. Analysis of the RAS mutation status will be carried out on blood samples taken at baseline, on those carried out at 20 +/-2 weeks after the start of treatment (in any case, prior to the second tumour assessment) and on the sample obtained upon progression, coinciding with routine clinical practices for collecting blood. Blood Samples will be collected to all subjects participating (119 subjects.)Objective to evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild type metastatic colorectal cancer.

No interventions assigned to this group

Patient RAS WT

As in cohort 1 blood samples will be collected for all subjects participating (119) 10 ml will be used for analysis of the RAS mutation status. The mutation status of BRAF and EGFR will be also analysed with the IdyllaTM (Biocartis) tests in this Cohort 2. In 20 patients included in Cohort 2, 10 ml additional taken at baseline will be used in order to determine the RAS mutation status by the BEAMing technique and 10 ml additional taken at disease progression will be used to determine the mutational profile in genes other than RAS by a NGS technique.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who give their informed consent in writing
* Subjects with metastatic colorectal cancer, measurable by RECIST, who start first-line treatment
* Male and female subjects, at least 18 years of age and of any ethnicity
* Subjects with a histologically-confirmed diagnosis of colorectal carcinoma with metastatic disease and wild-type RAS.

Exclusion Criteria

* Pregnant or breastfeeding women
* Subjects who have previously received monoclonal antibodies against EGFR (cetuximab or panitumumab), small-molecule EGFR inhibitors (such as erlotinib) or other biological cancer treatments
* History of another solid or haematological tumour in the previous 5 years, except a history of basal cell carcinoma of the skin or pre-invasive cervical cancer
* Subjects who are participating or have participated in a clinical trial in the 30 days prior to inclusion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No